Industry and peer comparisons of companies that report before Pfizer: Johnson & Johnson ( JNJ) recently beat earnings by a penny with $1.30 EPS. Wall Street wasn't pleased and shares have fallen about $2 a share to trade near $67.50. Analysts as a whole like this company. Currently, J&J has 15 buy recommendations out of 23 analysts covering the company, eight holds and zero sell ratings. Over half the analysts covering J&J rate it as a buy or a strong buy. J&J has appreciated 2.2% in the last year, and the average analyst target price for J&J is $74.60. J&J has a sizeable short interest of 9.5%.